ASCO Group Revenue and Competitors

Aberdeen, ID USA

Location

N/A

Total Funding

Energy/Oil

Industry

Estimated Revenue & Valuation

  • ASCO Group's estimated annual revenue is currently $453.4M per year.(i)
  • ASCO Group's estimated revenue per employee is $343,000

Employee Data

  • ASCO Group has 1322 Employees.(i)
  • ASCO Group grew their employee count by 4% last year.

ASCO Group's People

NameTitleEmail/Phone
1
Chief Accountant • FinanceReveal Email/Phone
2
Head Wells and Marine OpsReveal Email/Phone
3
Head Environmental and DecommissioningReveal Email/Phone
4
Operations DirectorReveal Email/Phone
5
Finance DirectorReveal Email/Phone
6
Group Chief Financial OfficerReveal Email/Phone
7
Group Innovation DirectorReveal Email/Phone
8
Group IT&S DirectorReveal Email/Phone
9
Finance Director - UKReveal Email/Phone
10
Managing Director UKReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.7M340%N/AN/A
#2
$77.3M28733%N/AN/A
#3
$453.4M13224%N/AN/A
#4
$120.4M393N/AN/AN/A
#5
$112.4M3675%N/AN/A
#6
$15M68-1%N/AN/A
#7
$39.6M1478%N/AN/A
#8
$211.9M692N/AN/AN/A
#9
$5.9M30-3%N/AN/A
#10
$58.2M216N/AN/AN/A
Add Company

What Is ASCO Group?

ASCO is the leading materials management and logistics company for the global energy industry. \n\nThe company offers an integrated service which includes end-to-end solutions spanning supply base management, materials and warehouse management, waste management, decommissioning, transport and logistics, training, personnel provision, fuel services and marine management.\n\nHeadquartered in Aberdeen, Scotland, ASCO operates from over 70 locations worldwide and employs c.1,500 people. \n\nWith over 50 years' of oil and gas knowledge, ASCO's experience and capability helps our customers by transforming operational efficiency, improving processes and continuously enhancing our services and systems.

keywords:N/A

N/A

Total Funding

1322

Number of Employees

$453.4M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ASCO Group News

2022-04-19 - CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy ...

Patients in both groups could receive up to four cycles of adjuvant chemotherapy, radiotherapy, or both. The primary endpoints were...

2022-04-19 - Selinexor in Previously Treated Advanced Dedifferentiated ...

Crossover was permitted in the placebo group upon disease progression. The primary endpoint was progression-free survival.

2022-04-17 - Factors Contributing to Mortality and Second Cancer ...

In analysis according to adverse health outcome risk groups ... group (HR = 8.73) and cancer mortality in the high-risk group (sHR = 5.44).

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$461M134454%N/A
#2
$463.4M1351N/AN/A
#3
$579.3M168910%N/A
#4
$620.8M181011%N/A
#5
$717.9M19356%N/A